Caris Life Sciences, Inc. CAI
Caris Life Sciences, Inc. (Nasdaq: CAI) is an oncology diagnostics company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Caris Detect | Multi-cancer early detection | device-combination | NA_NON_THERAPEUTIC |
| MI Profile Platform (MI Cancer Seek NGS component) | Oncology molecular profiling / therapy selection | device-combination | NA_NON_THERAPEUTIC |
| Caris Assure Platform | Blood-based molecular profiling / therapy selection / MRD tracking | device-combination | NA_NON_THERAPEUTIC |
| Caris MI Clarity | HR-positive/HER2-negative node-negative early-stage breast cancer prognosis | device-combination | NA_NON_THERAPEUTIC |
| Caris ChromoSeq | Myeloid malignancies genomic evaluation | device-combination | NA_NON_THERAPEUTIC |
| Precision Whole Genome Platform | Oncology WGS profiling | device-combination | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other oncology companies
- GRAIL, Inc. GRAL
- Personalis, Inc. PSNL
- AnaptysBio, Inc. ANAB
- Alpha Tau Medical Ltd. DRTS
- Freenome, Inc. FRNM
- Profound Medical Corp. PROF
- Burning Rock Biotech Ltd BNR
- Sensus Healthcare, Inc. SRTS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.